Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen
2022
De Koster, Jenne | Tena, Jezaniah‐Kira | Stegemann, Michael R.
BACKGROUND: The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti‐inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD. METHODS: Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin‐ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post‐treatment. Individual respiration and depression scores were determined at 6 h post‐treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21. RESULTS: The tulathromycin‐ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin‐ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin‐ketoprofen‐treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score). CONCLUSION: Efficacy of tulathromycin‐ketoprofen for the treatment of BRD was non‐inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par National Agricultural Library
Découvrez la collection de ce fournisseur de données dans AGRIS